Caribou Biosciences (CRBU) versus Its Competitors Financial Analysis

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Caribou Biosciences to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

Insider and Institutional Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Caribou Biosciences and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caribou Biosciences 1 4 1 1 2.29
Caribou Biosciences Competitors 9923 15317 45692 1603 2.54

Caribou Biosciences currently has a consensus price target of $4.50, suggesting a potential upside of 1,174.79%. As a group, “Biotechnology” companies have a potential upside of 131.47%. Given Caribou Biosciences’ higher probable upside, equities research analysts clearly believe Caribou Biosciences is more favorable than its rivals.

Valuation and Earnings

This table compares Caribou Biosciences and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Caribou Biosciences $9.44 million -$148.12 million -0.34
Caribou Biosciences Competitors $768.41 million $11.71 million -18.32

Caribou Biosciences’ rivals have higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Caribou Biosciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caribou Biosciences -1,085.00% -102.74% -69.45%
Caribou Biosciences Competitors -12,224.09% -202.33% -31.23%

Risk & Volatility

Caribou Biosciences has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, Caribou Biosciences’ rivals have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Summary

Caribou Biosciences beats its rivals on 7 of the 13 factors compared.

About Caribou Biosciences

(Get Free Report)

Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients. The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.